Publications
372
Citations
14,945
Est. group size
—
Recurring co-author estimate
Active years
37
Publishing since 1990
This researcher focuses on head and neck cancer, combining clinical surgical work (including microvascular reconstructive surgery) with laboratory studies on drugs that target cancer cell survival pathways, such as Bcl-2 and survivin inhibitors. Recent work also explores using artificial intelligence to analyze tissue images (H&E stains) to predict which patients will respond to immunotherapy. This body of work spans surgical oncology, drug resistance mechanisms, and emerging computational pathology tools.
Publication output was relatively steady (10-20 per year) from 2017-2022, then showed a large spike in 2023 (70 publications, partly reflecting supplementary data records for prior studies) followed by a marked decline in 2024-2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- 1405P AI informed virtual immunocyte profiling from H&E images predicts immunotherapy response (VIPER) in head and neck squamous cell carcinoma
Annals of Oncology · 2025
- Updates in Assisted Advanced Technology for Microvascular Free Tissue Transfer in Head and Neck Surgery
Facial Plastic Surgery Clinics of North America · 2024
- 1205 AI-informed integration of spatial architecture of collagen and tumor-infiltrating lymphocytes from H&E images predicts response to immunotherapy in head and neck squamous cell carcinoma patients
Regular and Young Investigator Award Abstracts · 2024
- Supplementary Table 2 from YM155 Reverses Cisplatin Resistance in Head and Neck Cancer by Decreasing Cytoplasmic Survivin Levels
2023
- Incidence and medical complications of COVID-19 in the total laryngectomy population: A population-based study
Oral Oncology · 2023
- Data from TW-37, a small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesis
2023
- Supplementary Data from TW-37, a small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesis
2023
- Supplementary Data from TW-37, a small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesis
2023
- Supplementary Figures from TW-37, a small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesis
2023
- Supplementary Figures from TW-37, a small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesis
2023
- Data from TW-37, a small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesis
2023
- Supplementary Figure 3 from YM155 Reverses Cisplatin Resistance in Head and Neck Cancer by Decreasing Cytoplasmic Survivin Levels
2023
- Supplementary Table 1 from YM155 Reverses Cisplatin Resistance in Head and Neck Cancer by Decreasing Cytoplasmic Survivin Levels
2023
- Supplementary Table 3 from YM155 Reverses Cisplatin Resistance in Head and Neck Cancer by Decreasing Cytoplasmic Survivin Levels
2023
- Supplementary Figure 1 from YM155 Reverses Cisplatin Resistance in Head and Neck Cancer by Decreasing Cytoplasmic Survivin Levels
2023
- Oral Oncology×13
- Head & Neck×11
- Otolaryngology×7
- The Laryngoscope×5
- Oncotarget×5
- Stephen Y. Kang
Medicine · The Ohio State University
- Avinash V. Mantravadi
Medicine · Indiana University
- Enver Özer
Medicine · The Ohio State University
- Amit Agrawal
Medicine · The Ohio State University
- Lauren E. Miller
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile